Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Nyradas NYX-PCSK9i with Statin Achieves 65% Cholesterol Reduction in Preclinical Study (ASX:NYR)

Nyrada Inc (ASX: NYR) (“Nyrada” or “the Company”) a preclinical stage, drug development company specialising in novel small molecule drugs to treat cardiovascular and neurolo...read more

Next Science - Zimmer complaint (ASX:NXS)

Next Science Limited (ASX:NXS) (Next Science / Company) advises that it has agreed to open negotiations with Zimmer, Inc (Zimmer), a global leader in orthopaedics and hip and knee replacement surger...read more

Nyrada - Improved Drug Candidate Selected for WRAIR Studies (ASX:NYR)

Nyrada Inc (ASX: NYR), a preclinical stage, drug development company specialising in novel small molecule drugs to treat cardiovascular and neurological diseases, today announces the selection of a ...read more

Next Science - Update on expected revenue for H1 (ASX:NXS)

Next Science Limited (ASX:NXS)(Next Science / Company) refers to the expected run rate for 1H 2021 stated in our quarterly activity report released on 28 January 2021 and wishes to advise that we ex...read more

Next Science - BlastX approved by TGA for sale in Australia (ASX:NXS)

Next Science Limited (ASX:NXS) (Next Science / Company) is delighted to announce that BlastXTM antimicrobial wound gel has been cleared by the Therapeutic Goods Administration (TGA). This TGA cle...read more

Next Science - 2021 AGM Presentation (ASX:NXS)

To view the presentation, download the attached PDF.

Next Science - 2021 AGM Chair & Managing Director Addresses (ASX:NXS)

I am delighted to bring you this Chairman’s report. Next Science is a relatively young company, with an exciting future ahead of it. There were many challenges in 2020, with key ones being ...read more

Noxopharm Lodges Patent for Major Septic Shock Opportunity (ASX:NOX)

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce lodgement of an international patent application aimed at protecting the use of Veyonda (idronox...read more

Noxopharm IONIC Immuno-Oncology Trial Commences (ASX:NOX)

Highlights: Ethics Approval received for IONIC-1 clinical trial, with trial to commence immediately in Australian hospitals IONIC-1 to test combination of Veyonda® with blockbuster Bristol...read more

NOXCOVID Trial Advances to Final Stage (ASX:NOX)

Positive review of hospitalized COVID-19 patients triggers approval to move from Part 1 to Part 2 of the trial Top dose of 1800 mg Veyonda daily to be used in final patient cohort Tests on blood ...read more

Noxopharm: Updated Corporate Presentation February-March 2021 (ASX:NOX)

Australian clinical stage drug development company, Noxopharm Limited (ASX:NOX), provides to shareholders and the market generally the attached corporate presentation ahead of a series of global vir...read more

Nyrada Reports Half Year FY2021 Results (ASX:NYR)

To view the report, download the attached PDF.

Noxopharm Announces LuPIN Trial Survival Outcome Confirmed by Conference Presentation (ASX:NOX)

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to provide a more detailed summary of the data from the LuPIN study that was formally presented to the Ameri...read more

Noxopharm Announces Global Conference To Hear of Major Survival Benefit in Prostate Cancer Patients (ASX:NOX)

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to report the publication in abstract form of the latest survival data from the LuPIN study ahead of a forma...read more

Nyrada Reports Further Results from Cholesterol Study (ASX:NYR)

Nyrada Inc (ASX: NYR) is pleased to report new additional exploratory results of its in vivo cholesterol efficacy study, first announced on 21 December 2020. The study used a mouse model that has be...read more

Viewing: 76 - 90 of 200 Previous | Next